Small-Cap Healthcare Comparison: Black Diamond vs. Entrada Therapeutics
1 report, 1 independent
Updated Oct 11
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Black Diamond Therapeutics and Entrada Therapeutics are both small-cap healthcare companies. A comparison of the two companies shows differences in institutional ownership, volatility, and profitability metrics. Black Diamond Therapeutics has a beta of 3.32, indicating higher volatility compared to Entrada Therapeutics, which has a beta of -0.24.
From themarketsdaily.com
Why it matters
The comparison highlights differences in how large money managers view the two companies, as 95.5% of Black Diamond Therapeutics shares are held by institutional investors, compared to 86.4% of Entrada Therapeutics shares. These differences in ownership and risk profile affect market perception of the companies.
From themarketsdaily.com